Innovent's First Mover Advantage for GLP-1 In China Will Be Long-Term Growth Driver

Innovent is a leading biotech company in China with strong roots in oncology, anchored its core PD-1 drug Tyvyt. However, its recently approved dual agonist GLP-1 drug in 2025 will be its long-term valuation driver given the PD-1 in China is now mature. We expect mazdutide, Innovent's GLP-1, to account for 25% of total revenue in 2027 from less than 5% in 2025. Mazdutide's advantage comes from its license agreements with Eli Lilly and first-mover advantage in China's GLP-1 market, which we estimate to have less than 1% penetration in 2025.